<DOC>
	<DOCNO>NCT02918305</DOCNO>
	<brief_summary>The REQUIRE STUDY multi-center , randomize , double-blind , sham-controlled study , aim confirm efficacy safety PRDS-001 ( ReCor Medical Inc. ParadiseÂ® Europe ) renal denervation therapy patient treatment resistance hypertension , comparison sham procedure .</brief_summary>
	<brief_title>Renal Denervation Quality 24-hr BP Control Ultrasound In Resistant Hypertension</brief_title>
	<detailed_description>Patients treatment resistance hypertension define patient treat 3 different class antihypertensive medication include diuretic .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>average office systolic BP 150 mmHg great office diastolic BP 90 mmHg great ( sit position ) 24hr ambulatory BP 140 mmHg great . Secondary hypertension ( sleep apnoea include . ) Type I diabetes uncontrolled Type II diabetes HbA1c 8.4 % great Known concurrent chronic active inflammatory bowel disease ( e.g . Crohn 's disease , ulcerative colitis etc . ) eGFR &lt; 40 mL/min/1.73m2 ( per predictive equation Japanese Society Nephrology ) Known severe cardiovascular event within 3 month severe cerebrovascular event Patients plan receive PCI operation iscaemic cardiovascular disease within 8 month Concurrent persistent atrial fibrillation Patients active implantable medical device Primary pulmonary hypertension Patients contraindicate , confirm intolerable anaphylactic reaction uncontrollable allergy contrast medium</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>denervation</keyword>
	<keyword>resistant hypertension</keyword>
</DOC>